Haemophilus Influenzae Type b Conjugate Vaccine (Chengda Bio)

Phase I: To evaluate the safety of Haemophilus influenzae type b conjugate vaccine in people aged 2 months (60-89 days) and above, and to provide a basis for the conduct of Phase III clinical trials. Phase III: Main objectives: (1) Compared with the control vaccine, to evaluate whether the proportion of anti-Hib-PRP antibody concentration ≥1.0μg/ml in the test group is non-inferior to that in the control group after Haemophilus influenzae type b conjugate vaccine is administered to healthy people aged 2 months (60-89 days) (0, 1, 2 months vaccination schedule), 6-11 months, and 1-5 years old; (2) Compared with the control vaccine, to evaluate the safety of Haemophilus influenzae type b conjugate vaccine.